Navigation Links
One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
Date:3/19/2008

Although Two-Thirds of Surveyed Physicians Anticipate an Increase in the Number of Patients Treated for Low HDL Over the Next Two years, 19 Percent

of Surveyed MCOs Will Not Add Novel HDL Drugs to Their Formularies,

According to a New Report from Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that approximately one-third of surveyed primary care physicians (PCPs) and cardiologists do not consider it necessary to treat low high- density lipoprotein (HDL) until patients' HDL levels drop below the recommended threshold established by the U.S. National Cholesterol Education Program's Adult Treatment Panel III guidelines.

The new Physician & Payer Forum primary market research report entitled Are Payers and Physicians Ready for a Paradigm Shift in Preventive Cardiology? An Assessment of Current and Future Use of HDL-Targeting Therapies finds that most surveyed PCPs and cardiologists anticipate that the number of patients treated for low HDL will increase due to the launch of new HDL-raising therapies. These drugs, which offer improved tolerability and/or efficacy compared with currently available agents, include Merck's Cordaptive, Merck's MK-0524B and novel agents such as Merck's anacetrapib and Roche's dalcetrapib. However, 19 percent of surveyed managed care organizations' (MCOs) pharmacy directors said that they would not add any novel HDL drug to their private plan formularies. The report finds that MCOs have lower efficacy expectations than physicians do for new HDL-raising therapies and are more willing to trade off improvements in efficacy in return for treatments that offer better safety and tolerability.

"MCO pharmacy directors say that the most important key factors that would affect their willingness to include a novel HDL-raising therapy into their private plan formularies include outcomes data, low cost and efficacy in reducing low-density lipoprotein (LDL) cholesterol or high triglycerides in addition to raising HDL," said Donny Wong, Ph.D., principal analyst at Decision Resources. "Drug companies are unlikely to get good formulary tier placement for novel HDL therapies on the basis of improved tolerability alone."

Are Payers and Physicians Ready for a Paradigm Shift in Preventive Cardiology? An Assessment of Current and Future Use of HDL-Targeting Therapies is based on a U.S. survey of 73 U.S. cardiologists, 73 PCPs, and 21 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About High-Density Lipoprotein Cholesterol

Patients with low levels of HDL cholesterol are at elevated risk for cardiovascular disease, even if their levels of LDL cholesterol are well controlled. An estimated 50 percent of cardiovascular events occur in patients with low HDL, an under-treated disorder that afflicts nearly 30 million individuals in the United States. In 2007, agents that target low HDL achieved less than $800 million in sales, compared with close to $8 billion achieved by statins targeting high LDL.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
2. Acute lung injury patients one-third less likely to die in closed model ICUs
3. Over one-third of former American football players had sexual relations with men, study says
4. One-Third of Popular Songs Refer to Substance Abuse
5. New Gallup Survey Finds Half of Los Angeles Area Residents Have Taken in a Near-Homeless Person, One-Third Fear Homelessness Themselves
6. AIDS Ignorance: One-Third of Adults Admit Little or No Knowledge of Pandemic
7. One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC
8. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
9. Kaiser Permanente Study Shows One-Third of Women Have Overactive Bladder, Incontinence or Other Pelvic Floor Disorders
10. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
11. Study finds primary care depression treatment often does not follow quality guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... be this year’s recipient of proceeds from its 14th Annual Clays for Kids ... E. County Road 30, Bennett, Colorado. , As part of BluSky’s partnership ...
(Date:5/26/2017)... ... 26, 2017 , ... “Cactus Jack: Against All Odds”: the story of Coach ... Jack: Against All Odds” is the creation of published author, Walter Hubbard, a retired ... Jack Carlisle’s third child Jane. Walter. Walter and Jane have three adult children ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... Medical Center CEO Mary Ellen, hospital employees, and town officials to celebrate the ... The facility was developed by Rendina as part of its ongoing relationship with ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, ... in New York City. He is known for his distinguished expertise and experience in ... Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... and interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance ... scalable and secure cloud platform for medical image management. At the core is ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... Mich. , May 8, 2017  Diplomat Pharmacy, ... WRB Communications, Inc. ("WRB"), a health care service ... . WRB specializes in relationship management programs ... WRB will join ... Diplomat,s commercialization support services for manufacturers, biotech firms, and ...
(Date:5/4/2017)... , May 4, 2017  A recent ... Control, Ultraviolet-C light as a means ... SmartUVC,s ability to reduce bioburden on anesthesia workstations. ... reduction on high-touch, complex medical equipment surfaces contaminated ... infections. "This study further validates the ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology: